Intensive therapy for tight glycemic control improves long-term outcomes in patients with T2DM. However, diabetes care is generally suboptimal, and up to two-thirds of people with T2DM do not achieve glycemic targets. T2DM patients are at increased risk for microvascular and macrovascular complications, depending upon the duration of diabetes and degree of hyperglycemia. The SGLT2 inhibitors are newer options for T2DM management that, unlike other antidiabetic agents, do not target insulin deficiency and resistance in T2DM, and therefore offer a different approach for managing this condition. Given their mechanism of action, the SGLT2 inhibitors can facilitate glycemic control while avoiding hypoglycemia, and promoting weight loss. They also exert beneficial effects on multiple cardiovascular and renal risk parameters, as demonstrated in recent trials, and may confer cardiovascular and renal protection. When used in combination therapy with other anti-diabetic agents for T2DM, the SGLT2 inhibitors can exert additive/synergistic effects.
This activity utilizes segments of a presentation by the faculty recorded at one of the Emerging Challenges in Primary Care symposia, to reinforce teaching points made during this program. Participants can expect to learn how to effectively integrate the SLGT2 class of medications into practice and the emerging data surrounding renal and macrovascular effects of diabetes treatments.
Gregg Sherman, MD
National Association for Continuing Education
Harvey C. Parker, Ph.D., CCMEP
National Association for Continuing Education
Joshua Kilbridge, President
San Francisco, CA
DISCLOSURE POLICY STATEMENT:
It is the policy of NACE to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. NACE assesses conflict of interest with its faculty, planners and managers of CME activities. Conflicts of interest that are identified are resolved by reviewing that presenter's content for fair balance and absence of bias, scientific objectivity of studies utilized in this activity, and patient care recommendations.
While NACE endeavors to review faculty content, it remains the obligation of each physician or other healthcare practitioner to determine the applicability or relevance of the information provided from this course in his or her own practice.
DISCLOSURE OF CONFLICTS OF INTEREST:
Robert S. Busch, MD, FACE serves as a speaker for Astra Zeneca, Eli Lilly, Boehringer Ingelheim, Novo Nordisk, and Shire. Dr. Busch also serves as a researcher for Astra Zeneca, Novo Nordisk, Janssen, and Amgen.
Luigi Meneghini, MD, MBA serves as a consultant and advisory board member for Novo Nordisk and Sanofi Aventis.
Gregg Sherman, MD has no real or apparent conflicts of interest to report.
Harvey Parker, PhD has no real or apparent conflicts of interest to report.
Joshua Kilbridge has no real or apparent conflicts of interest to report.
DISCLOSURE OF UNLABELED USE:
NACE requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
The opinions expressed during the educational activity are those of the faculty and do not necessarily represent the views of NACE. The information is presented for the purpose of advancing the attendees' professional development.
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222.
This CME activity was planned and produced in accordance with the ACCME Essentials and the AANP CE Standards and Policies and AANP Commercial Support Standards.
For CME questions, please contact: NACE at email@example.com
Contact this CME provider for privacy and confidentiality policy statement information at:
CREDIT DESIGNATION STATEMENT:
The National Association for Continuing Education designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim credit commensurate with the extent of their participation in the activity.
National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1.0 hr contact hours of continuing education (which includes .50 hours of pharmacology)
TO OBTAIN CME CREDITS:
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the post-test and activity evaluation.
- Physicians who successfully complete the post-test and evaluation will receive CME credit.
- Nurse Practitioners who successfully complete the post-test and evaluation will receive AANP CE credit.
- You must score 60% or higher on the post-test to receive credit for this activity.
- All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
: Internet CME Activity
ESTIMATED TIME TO COMPLETE: 60 minutes
This activity is sponsored by National Association for Continuing Education.
This activity is supported by educational funding provided by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.
If you have any questions regarding this activity, send an email to firstname.lastname@example.org.
Copyright © 2017 National Association for Continuing Education. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of NACE is prohibited.